Skip to main content
HYTN Innovations Inc. logo

HYTN Innovations Inc. — Investor Relations & Filings

Ticker · HYTN ISIN · CA40443L1040 LEI · 894500ZEFRLAROPRBH27 CSE Manufacturing
Open in API
Filings indexed 172 across all filing types
Latest filing 2026-04-24 Regulatory Filings
Country CA Canada
Listing CSE HYTN

About HYTN Innovations Inc.

https://hytn.ca/

HYTN Innovations Inc. formulates and manufactures premium products containing psychoactive and psychotropic compounds, including cannabinoids and psilocybin. Operating a GMP-certified facility, the company specializes in producing Active Pharmaceutical Ingredients (APIs) and finished goods for global pharmaceutical export, holding a Health Canada Drug Establishment License. HYTN is recognized as one of the few global sites certified for the cultivation, processing, and release of psilocybin mushrooms. Its unique selling proposition is the proprietary Elevation Technology®, a nano-emulsification platform that creates stable, highly bioavailable, rapid-onset formulations. For consumer markets, HYTN manufactures and distributes branded cannabis products such as sugar-free beverages, nano-shots, and edibles.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a corporate press release announcing the extension of a marketing engagement (MCS Market Communication Service GmbH) and is not a financial report, management change, capital raise, or any other specific filing type. It does not present financial results (ER/IR), governance materials (AGM‐R/PSI), or regulatory/legal disclosures (LTR). It is best classified as a general regulatory announcement/fallback category. Therefore, the filing type is RNS.
2026-04-24 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a corporate press release announcing the extension of a marketing services engagement with MCS Market Communication Service GmbH. It contains no financial results, no board or management changes, no share issuances or capital changes, no proxy or voting information, no M&A or legal proceedings, nor any mention of reporting schedules or published reports. It does not match any of the highly specific categories (e.g., earnings release, M&A, interim report, etc.), so it falls into the fallback category for miscellaneous regulatory announcements. Therefore, it should be classified as a general Regulatory Filing (RNS).
2026-04-24 English
Material change report - English.pdf
Board/Management Information Classification · 1% confidence The document is a press release announcing resignations and appointments of board members and senior management (directors and C-level officers). This fits exactly the Board/Management Information category.
2026-04-24 English
Material change report - English.pdf
Regulatory Filings Classification · 1% confidence The document is a Canadian Form 51-102F3 Material Change Report describing the spin-out of an internal peptide drug business and related concurrent financing. It is a mandatory regulatory filing under NI 51-102 and does not fit neatly into categories like M&A (no merger/takeover), Capital/Financing Update (not purely financing), or others. Therefore it falls under the fallback “Regulatory Filings” category.
2026-04-24 English
News release - English.pdf
M&A Activity Classification · 1% confidence The document is a corporate press release announcing the Board-approved spin-out (carve-out) of a peptide drug development business into a new subsidiary (“SpinCo”), detailing asset transfers, share consideration, and concurrent financing. This is a strategic corporate transaction akin to a spin-off, fitting the M&A Activity category. It is not financial results, regulatory filings for dividend or board changes, or an annual/interim report. Therefore it is classified as M&A Activity (TAR).
2026-04-24 English
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a corporate press release announcing a proposed spin-out transaction (asset transfer to SpinCo) coupled with a concurrent non-brokered private placement financing of up to CAD $1,000,000. It is not an earnings release, regulatory audit, M&A takeover, or management report, nor is it simply a notice of dividend or proxy solicitation. The primary focus is on financing activities and capital structure changes tied to the spin-out, which aligns with the “Capital/Financing Update” category (CAP).
2026-04-24 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.